After inclusion criteria filtration, we prioritized two FDA-approved TBK1 inhibiting chemicals that act as repurposing drugs for treating certain ALS subtypes and validated their efficacies by in vitro pharmacological analyses. The gene discussed is TBK1; the disease is amyotrophic lateral sclerosis.